ETEST DORIPENEM - ANTIMICROBIAL SUSCEPTIBILITY TEST - MIC AT 0.002-32 UG/ML
K081325 · Ab Biodisk · JWY · Jul 24, 2008 · Microbiology
Device Facts
| Record ID | K081325 |
| Device Name | ETEST DORIPENEM - ANTIMICROBIAL SUSCEPTIBILITY TEST - MIC AT 0.002-32 UG/ML |
| Applicant | Ab Biodisk |
| Product Code | JWY · Microbiology |
| Decision Date | Jul 24, 2008 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.1640 |
| Device Class | Class 2 |
Intended Use
This submission is for Etest Doripenem for MIC determinations across 0.002-32 µg/mL with Gram negative aerobic bacteria such as Enterchacteriaceae, Accretobacer baumanii, Pseudomonas aeraginesa and Gram negative anaerobic bacteria such as Bacteroides aacae, B. fragilis, B.thetaiotaorracron, B. uniformis and B. ulgatus. Etest is a quantitative technique for determination of antimicrobial susceptibility of both nonfastidious Gram negative and Gram positive aerobic bacteria such as Enterchaceriane, Pseudomnas, Staphylococus and Enteroxous species and fastidious bacteria, such as anaerobes, N. gonombeae, S. preumoniae, Streptoxous and Haemophilus species. The system comprises a predelined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC) in ug/ mL of different antimicrobial agents against microorganisms as tested on agar using overnight incubation.
Device Story
Etest is a quantitative antimicrobial susceptibility test; utilizes predefined antibiotic gradient on a test strip; applied to inoculated agar plates; incubated overnight. Principle: antibiotic diffuses into agar, creating a concentration gradient; bacterial growth inhibition forms an elliptical zone of inhibition. Intersection of growth with the strip indicates the Minimum Inhibitory Concentration (MIC) in µg/mL. Used in clinical microbiology laboratories by trained technicians. Provides quantitative MIC values to guide clinicians in selecting appropriate antibiotic therapy for bacterial infections. Benefits: precise susceptibility data compared to qualitative methods; aids in optimizing dosing regimens.
Clinical Evidence
No clinical data provided. Substantial equivalence is based on bench testing of the Etest system's performance in determining MIC values for Doripenem against specified bacterial isolates compared to reference methods.
Technological Characteristics
In vitro diagnostic device; consists of a reagent-impregnated strip creating a stable antibiotic concentration gradient. Principle: agar diffusion. Dimensions: strip form factor. Connectivity: none (standalone). Sterilization: N/A. Software: none.
Indications for Use
Indicated for MIC determination of Doripenem (0.002-32 µg/mL) in Gram-negative aerobic bacteria (e.g., Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa) and Gram-negative anaerobic bacteria (e.g., Bacteroides spp.). Also indicated for general antimicrobial susceptibility testing of nonfastidious Gram-negative/positive aerobic bacteria and fastidious bacteria (anaerobes, N. gonorrhoeae, S. pneumoniae, Streptococcus, Haemophilus).
Regulatory Classification
Identification
An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.
Related Devices
- K102668 — ETEST TOBRAMYCIN 0.016-256 UG/ML AND 0.064-1024 UG/ML · BIOMERIEUX · Nov 17, 2010
- K981137 — ETEST CEFOTAXIME · Ab Biodisk · Jun 9, 1998
- K052366 — ETEST TIGECYCLINE GRAM POSITIVE AND GRAM NEGATIVE AEROBIC BACTERIA, STREPTOCOCCUS SPP. AND ANAEROBIC BACTERIA · Ab Biodisk · Oct 13, 2005
- K980342 — ETEST CHLORAMPHENICAL · Ab Biodisk · May 29, 1998
- K983027 — TRIMETHOPRIM/SULPHAMETHOXAZOLE · Ab Biodisk · Oct 2, 1998
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three curved lines representing its wings. The eagle is facing to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Asa Karlsson Quality Assurance and Regulatory Manager AB BIODISK Dalvägen 10 169 56 Solna, Sweden
JUL 2 4 2008
Re: k081325
Trade/Device Name: Etest® Antimicrobial Susceptibility Test – Doripenem MIC at 0.002-32 µg/mL Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Regulatory Class: Class II Product Code: JWY Dated: May 6, 2008 Received: May 12, 2008
Dear Ms.Karlsson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federall Food, Drug and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, isting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Degister.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must COMPLY with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{1}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510/k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sally attaym
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## Indications For Use
510(k) Number (if known): K081325
Device Name: Etest Antimicrobial Susceptibility Test - Doripenem MIC at 0.002-32 ug/mL.
Indications For Use: This submission is for Etest Doripenem for MIC determinations across 0.002-32 µg/mL with Gram negative aerobic bacteria such as Enterchacteriaceae, Accretobacer baumanii, Pseudomonas aeraginesa and Gram negative anaerobic bacteria such as Bacteroides aacae, B. fragilis, B.thetaiotaorracron, B. uniformis and B. ulgatus.
Etest is a quantitative technique for determination of antimicrobial susceptibility of both nonfastidious Gram negative and Gram positive aerobic bacteria such as Enterchaceriane, Pseudomnas, Staphylococus and Enteroxous species and fastidious bacteria, such as anaerobes, N. gonombeae, S. preumoniae, Streptoxous and Haemophilus species. The system comprises a predelined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC) in ug/ mL of different antimicrobial agents against microorganisms as tested on agar using overnight incubation.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Freddie Poole
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K081325